US3524858A - 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid - Google Patents

1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid Download PDF

Info

Publication number
US3524858A
US3524858A US639304A US3524858DA US3524858A US 3524858 A US3524858 A US 3524858A US 639304 A US639304 A US 639304A US 3524858D A US3524858D A US 3524858DA US 3524858 A US3524858 A US 3524858A
Authority
US
United States
Prior art keywords
dihydro
methylenedioxy
ethyl
percent
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US639304A
Inventor
Daniel Kaminsky
Robert I Meltzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Pharmaceutical Co filed Critical Warner Lambert Pharmaceutical Co
Application granted granted Critical
Publication of US3524858A publication Critical patent/US3524858A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • R represents alkyl, substituted lower alkyl, cycloalkyl, alkenyl and aralkyl; R represents O-alkyl, O-mono or dialkylaminoalkyl, O-cycloalkyl, NH-alkyl, NH-aryl,
  • the present invention relates to anti-bacterial compositions containing as active ingredients, 1,4-dihydro-1-R-6,7- methylenedioxy-4-ox-o-3-quinoline carboxylic acid derivatives of the formula:
  • NHCOOR in which R is lower alkyl or aralkyl and R is lower alkyl or R and R taken together with the nitrogen atom may constitute a cyclic moiety such as morpholino, piperidino, or piperazino, etc., and R may also be any readily hydrolyzable group, such as a thioester nitrile, or the like.
  • R, R R and R alkyl is meant to include those alkyl groups containing 1 to 12 carbon atoms in a straight or branch chain such as methyl, ethyl, propyl, isopropyl, and the like; cycloalkyl is meant to include from 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclohexyl, and the like; aralkyl is meant to include both monohomocyclic ring systems, such as 'benzyl, as well as heteroaromatic ring systems such as pyridyl, furyl, and the like.
  • the definitions R, R R and 3,524,858 Patented Aug. 18, 1970 R as used hereinafter are to be considered to have the meanings defined above.
  • compositions of this invention exhibit potent antibacterial activity particularly against gram negative bacteria, such as the Escherichia group and the Proteus group. Accordingly, they are useful as anti-bacterial agents in the treatment of mammals, such as dogs, guinea pigs, cats, monkeys, and the like, which are infected with bacteria susceptible to these agents.
  • mammals such as dogs, guinea pigs, cats, monkeys, and the like, which are infected with bacteria susceptible to these agents.
  • known pharmaceutical carriers such as lactose, starch, dicalcium phosphates, syrup, and the like, to yield various dosage forms such as tablets, suspensions and the like, with the active ingredient being present in amounts of from about to 500 mg. per dosage unit.
  • sten'le vehicles such as sterile water, or sterile isotonic saline to form dosage forms suitable for parental administration.
  • dosage forms may be compounded according to standard pharmaceutical art. Generally, a dosage regimen of about 100 mg. to 1500* mg, preferably about 250 mg., 3 or 4 times daily, orally or by injection are recommended to treat bacterial infections caused by these gram-negative bacteria.
  • a surprising property of these compositions resides in the discovery that they are more slowly metabolized in the mammalian body and consequently, they are longer acting when compared with other quinoline compounds such as those disclosed in U.S. Pat. No. 3,287,- 458. Because of this prolonged activity, the dosage that is necessary to be administered to a host may be considerably reduced.
  • the compounds of this invention may also be administered in admixture with animal foodstuffs, for example, they may be mixed from 1 to 25% by weight with foodstuffs such as corn meal, water, and the like.
  • compositions may comprise from about 1 to 20% by weight of the selected active ingredient and such standard pharmaceutical diluents which are commonly used in the manufacture of topical compositions, such as talc, Vaseline, or other hydrophobic or hydrophilic ointment bases, and the like. These compositions are applied to infected sites.
  • compositions of this invention may also include other known anti-bacterials, such as the tetracyclines, the nitrofurans, the sulfa drugs, and the like to enhance their anti-bacterial spectrum.
  • the active ingredients of this invention are prepared by four different methods.
  • Method A a compound of the formula:
  • Example 2 Cyclohexyl 1-ethyl-1,4 dihydro 4 oxo-6,7-methylenedioxy-quinoline-3-carboxylate.
  • 6 g. (0.06 mole) of freshly distilled cyclohexanol and 30 g. of pyridine was heated for 2 hr. on a steam bath. The volatiles were removed in vacuo and the residue was triturated several times with water and filtered.
  • the crude product was recrystallized from 3:1 CCLpCellosolve B yielding 15.4 g. (90%) of cyclohexyl l-ethyl-1,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinoline-carboxylate, M.P. 204-206".
  • Example 3 Following the procedure of Example 2 and employing analogous reaction conditions, but using ethanol, instead of cyclohexanol, there was obtained ethyl 1-ethy1-1,4- dihydro-6,7-methylenedioxy-4 oxo 3 quinolinecarboxylate, M.P. 177-178".
  • Example 4 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-propanol instead of cyclohexanol, there was obtained propyl 1- ethyl-1,4 dihydro 6,7 methylenedioxy 4 oxo-3- quinolinecarboxylate, M.P. 158-160.
  • Example 5 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-butanol instead of cyclohexanol, there was obtained butyl l-ethyl- 1,4 dihydro 6,7 methylenedioxy 4 oxo-3-quinoline carboxylate, M.P. 131-133.
  • Example 6 Following the procedure of Example 2 and employing analogous reaction conditions, but using t-amyl alcohol instead of cyclohexanol, there was obtained tert-amyl 1-ethyl-1,4 dihydro 6,7 methylenedioxy 4-oxo-3- quinolinecarboxylate, M.P. 172-173.
  • Example 7 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-hexyl alcohol instead of cyclohexanol, there was obtained hexyl l-ethyl- 1,4 dihydro 6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. -92".
  • Example 8 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-decyl alcohol instead of cyclohexanol, there was obtained decyl 1- ethyl 1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. 99-101".
  • Example 9 Following the procedure of Example 2 and employing analogous reaction conditions, but using diethylaminoethanol, instead of cyclohexanol, there was obtained 2- (diethylamino)ethyl 1 ethyl 1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. 108-109".
  • Example 10 The acid chloride obtained by treatment of 1,4-dihydro- 1 methyl 6,7 methylenedioxy 4-oxo-3-quinolinecarboxylic acid with thionyl chloride as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1,4 dihydro 1-methyl-6,7-methylenedioxy-4- oxo-3-quinolinecarboxylate, M.P. 202-203".
  • Example 11 The acid chloride obtained by treatment of 1-butyl-1,4- dihydro-6,7-methylenedioxy-4-oxo-3-quinoline carboxylic acid with thionyl chloride, as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1 butyl 1,4 dihydro-6,7-methylenedioxy-4-oxo-3-quinoline carboxylate, M.P. 117-119".
  • Example 2 Following the procedure of Method C, Example 1, and using m-anisidine there was obtained 1-ethyl-1,4-dihydro- N (m methoxyphenyl) 6,7-methylenedioxy-4-oxo3- quinoline carboxamide, M.P. 240-241 Analysis.-Calcd. for C H N 0 (percent): C, 65.56; H, 4.95; N, 7.65. Found (percent): C, 65.50; H, 5.02; 'N, 7.41.
  • R is lower alkyl, hydroxy-lower alkyl, carboxylower alkyl, lower alkenyl, or cycloalkyl, in which cycloalkyl has from 3 to 8 carbon atoms;
  • R is NHOH, NHCOOR NH-Q-ORz, and OCHzCHzN ⁇ in which R is lower alkyl.
  • R is C l-I and R1 iS 4.
  • R is C H and R1 is OCHB 5.
  • R is C H and R1 is OCH2CH2N(C2H5)2.

Description

United States Patent 1,4 DlHYDRO-l-SUBSTITUTED ALKYL-6,7-METH- YLENEDIOXY 4 OXOQUINOLINE-S-CARBOX- YLIC ACID Daniel Kaminsky, Parsippauy, and Robert I. Meltzer,
Rockaway, N.J., assignors to Warner-Lambert Pharmaceutical Company, Morris Plains, NJ., 2 corporation of Delaware No Drawing. Filed May 18, 1967, Ser. No. 639,304
Int. Cl. C07d 33/56 US. Cl. 260-287 Claims ABSTRACT OF THE DISCLOSURE The present invention relates to compositions of matter containing quinolines of the formula:
(1? 04 UjTman N wherein R represents alkyl, substituted lower alkyl, cycloalkyl, alkenyl and aralkyl; R represents O-alkyl, O-mono or dialkylaminoalkyl, O-cycloalkyl, NH-alkyl, NH-aryl,
NHCOOR NHOR, or any readily hydrolyzable group. These compounds are useful as anti-microbial agents.
The present invention relates to anti-bacterial compositions containing as active ingredients, 1,4-dihydro-1-R-6,7- methylenedioxy-4-ox-o-3-quinoline carboxylic acid derivatives of the formula:
mono or dialkylaminoalkyl, NH-lower alkyl, NH-aralkyl, NH-aryl,
where n is 1 to 4, NHCOOR in which R is lower alkyl or aralkyl and R is lower alkyl or R and R taken together with the nitrogen atom may constitute a cyclic moiety such as morpholino, piperidino, or piperazino, etc., and R may also be any readily hydrolyzable group, such as a thioester nitrile, or the like.
In the above definitions of R, R R and R alkyl is meant to include those alkyl groups containing 1 to 12 carbon atoms in a straight or branch chain such as methyl, ethyl, propyl, isopropyl, and the like; cycloalkyl is meant to include from 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclohexyl, and the like; aralkyl is meant to include both monohomocyclic ring systems, such as 'benzyl, as well as heteroaromatic ring systems such as pyridyl, furyl, and the like. The definitions R, R R and 3,524,858 Patented Aug. 18, 1970 R as used hereinafter are to be considered to have the meanings defined above.
The compositions of this invention exhibit potent antibacterial activity particularly against gram negative bacteria, such as the Escherichia group and the Proteus group. Accordingly, they are useful as anti-bacterial agents in the treatment of mammals, such as dogs, guinea pigs, cats, monkeys, and the like, which are infected with bacteria susceptible to these agents. In order to use these compounds, they are combined with known pharmaceutical carriers, such as lactose, starch, dicalcium phosphates, syrup, and the like, to yield various dosage forms such as tablets, suspensions and the like, with the active ingredient being present in amounts of from about to 500 mg. per dosage unit. They may also be combined with sten'le vehicles, such as sterile water, or sterile isotonic saline to form dosage forms suitable for parental administration.
These dosage forms may be compounded according to standard pharmaceutical art. Generally, a dosage regimen of about 100 mg. to 1500* mg, preferably about 250 mg., 3 or 4 times daily, orally or by injection are recommended to treat bacterial infections caused by these gram-negative bacteria. A surprising property of these compositions resides in the discovery that they are more slowly metabolized in the mammalian body and consequently, they are longer acting when compared with other quinoline compounds such as those disclosed in U.S. Pat. No. 3,287,- 458. Because of this prolonged activity, the dosage that is necessary to be administered to a host may be considerably reduced.
The compounds of this invention may also be administered in admixture with animal foodstuffs, for example, they may be mixed from 1 to 25% by weight with foodstuffs such as corn meal, water, and the like.
The compounds of this invention may also be used in a form suitable for topical application. Such compositions may comprise from about 1 to 20% by weight of the selected active ingredient and such standard pharmaceutical diluents which are commonly used in the manufacture of topical compositions, such as talc, Vaseline, or other hydrophobic or hydrophilic ointment bases, and the like. These compositions are applied to infected sites.
The compositions of this invention may also include other known anti-bacterials, such as the tetracyclines, the nitrofurans, the sulfa drugs, and the like to enhance their anti-bacterial spectrum.
The active ingredients of this invention are prepared by four different methods. In the first method (referred to as Method A in the examples below) a compound of the formula:
0 0 Q WC 0 Cl CH2 W a Ra In the third method, (referred to as Method C in the examples) compound II is treated with hydroxylamine or substituted hydroxylamines to yield compounds wherein R is NHOH or NHO R.
In the fourth method (referred to as Method D in the examples) compound II is treated with a carbamate ester (such as ethyl carbamate) to yield compounds wherein R is NHCOOR. Starting compound II is obtained by treating quinolines of the formula:
O u 4 lo 0 o n C 2 i ,1
R (III) with thionyl chloride, oxalyl chloride or other agents generally used to convert acids to acid chlorides. Compound IH is described and disclosed in US. Pat. 3,287,458.
The following examples are included in order further to illustrate the invention.
METHOD A Example 1 1 ethyl 1,4 dihydro-4-oxo-6,7-methylenedioxyquinoline-3-carbonyl chloride.-Thionyl chloride (13.2 g., 0.11 mole) was added to a slurry of 26.1 g. (0.1 mole) of pure l-ethyl-l,4-dihydro-4-oxo-6,7 methylenedioxy-3-quinoline carboxylic acid in 100 ml. dry benzene and the mixture was refluxed for 12 hr. Petroleum ether (250 ml.) was added and the mixture filtered to yield 29 g. of 1-ethyl-1,4 dihydro 4-oxo-6,7-methylenedioxy quinoline 3 carbonyl chloride as yellow brown solid, M.P. 235-236 (dec.). The crude solid was refiuxed with 500 ml. of CH CI and filtered hot to yield 24.3 g. (87%) of light brown solid, 1-ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxy quinoline 3 carbonyl chloride, M.P. 245 (dec.).
Analysis.Calcd. for C H ClNO (percent): C, 55.83; H, 3.60; N, 5.01; CI, 12.68. Found (percent): C, 56.03; H, 3.87; N, 4.94; Cl, 12.87.
Example 2 Cyclohexyl 1-ethyl-1,4 dihydro 4 oxo-6,7-methylenedioxy-quinoline-3-carboxylate.A mixture of 14 g. (0.05 mole) of l-ethyl-1,4-dihydro-4-oxo-6,7 methylenedioxy-quinoline-3-carbonyl chloride. 6 g. (0.06 mole) of freshly distilled cyclohexanol and 30 g. of pyridine was heated for 2 hr. on a steam bath. The volatiles were removed in vacuo and the residue was triturated several times with water and filtered. The crude product was recrystallized from 3:1 CCLpCellosolve B yielding 15.4 g. (90%) of cyclohexyl l-ethyl-1,4-dihydro-6,7-methylenedioxy 4 oxo 3 quinoline-carboxylate, M.P. 204-206".
Analysis.Calcd. for C H NO (percent): C, 66.46; H, 6.16; N, 4.08. Found (percent): C, 66.46; H, 6.24; N, 3.91.
Example 3 Following the procedure of Example 2 and employing analogous reaction conditions, but using ethanol, instead of cyclohexanol, there was obtained ethyl 1-ethy1-1,4- dihydro-6,7-methylenedioxy-4 oxo 3 quinolinecarboxylate, M.P. 177-178".
Analysis.Calcd, for C -H NO (percent): C, 62.28; H, 5.23; N, 4.48. Found (percent): C, 61.99; H, 5.07; N, 4.71.
Example 4 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-propanol instead of cyclohexanol, there was obtained propyl 1- ethyl-1,4 dihydro 6,7 methylenedioxy 4 oxo-3- quinolinecarboxylate, M.P. 158-160.
4 Analysis.Calcd. for C16H1'1NO5 (percent): C, 63.36; H, 5.56; N, 4.62. Found (percent): C, 63.13; H, 5.72; N, 4.74.
Example 5 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-butanol instead of cyclohexanol, there was obtained butyl l-ethyl- 1,4 dihydro 6,7 methylenedioxy 4 oxo-3-quinoline carboxylate, M.P. 131-133.
Analysis.--Calcd. for C H NO (percent): C, 64.35; H, 6.04; N, 4.41. Found (percent): C, 64.23; H, 5.94; N, 4.23.
Example 6 Following the procedure of Example 2 and employing analogous reaction conditions, but using t-amyl alcohol instead of cyclohexanol, there was obtained tert-amyl 1-ethyl-1,4 dihydro 6,7 methylenedioxy 4-oxo-3- quinolinecarboxylate, M.P. 172-173.
Analysis.-Calcd. for C H NO (percent): C, 65.24; H, 6.39; N, 4.23. Found (percent): C, 65.16; H, 6.36; N, 4.46.
Example 7 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-hexyl alcohol instead of cyclohexanol, there was obtained hexyl l-ethyl- 1,4 dihydro 6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. -92".
Analysis.--Calcd. for C H NO (percent): C, 66.07; H, 6.71; 'N, 4.06. Found (percent): C, 65.90; H, 6.81; N, 419.
Example 8 Following the procedure of Example 2 and employing analogous reaction conditions, but using n-decyl alcohol instead of cyclohexanol, there was obtained decyl 1- ethyl 1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. 99-101".
Analysis.-Calcd. for C H NO (percent): C, 68.80; H,- 7.78; N, 3.49. Found (percent): C, 69.07; H, 7.89; N, 3.70.
Example 9 Following the procedure of Example 2 and employing analogous reaction conditions, but using diethylaminoethanol, instead of cyclohexanol, there was obtained 2- (diethylamino)ethyl 1 ethyl 1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylate, M.P. 108-109".
Ana-lysis.-Calcd. for C H N O (percent): C, 63.32; H, 6.71; N, 7.77. Found (percent): C, 63.52; H, 6.75 N, 7.48.
Example 10 The acid chloride obtained by treatment of 1,4-dihydro- 1 methyl 6,7 methylenedioxy 4-oxo-3-quinolinecarboxylic acid with thionyl chloride as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1,4 dihydro 1-methyl-6,7-methylenedioxy-4- oxo-3-quinolinecarboxylate, M.P. 202-203".
Analysis.Calcd. for C H NO (percent): C, 61.09; H, 4.76; N, 5.09. Found (percent): C, 61.26; H, 4.99; N, 5.08.
Example 11 The acid chloride obtained by treatment of 1-butyl-1,4- dihydro-6,7-methylenedioxy-4-oxo-3-quinoline carboxylic acid with thionyl chloride, as in Method A, Example 1, was treated, without isolation, with ethanol to yield ethyl 1 butyl 1,4 dihydro-6,7-methylenedioxy-4-oxo-3-quinoline carboxylate, M.P. 117-119".
Analysis.-Calcd. for C H NO (percent: C, 64.35; H, 6.04; N, 4.41. Found (percent): C, 64.51; H, 6.23; N, 4.50.
METHOD B Example 1 N (2 diethylaminoethyl)-l-ethyl-1,4-dihydro-4-oxo- 6,7-methylenedioxy-quinoline-3-carboxamide.A mixture of 8.4 g. (0.03 mole) of l-ethyl-1,4-dihydro-4-oxo-6,7- methylenedioxy quinoline-3-car-bonyl chloride, 4.6 g. (0.04 mole) of N,N-diethyl ethylenediamine and 150 ml. of benzene was refluxed for 8 hr. The volatiles were removed under aspirator vacuum and the residue was triturated with 5% NaOH solution and recrystallized from aqueous isopropyl alcohol yielding 10.2 g. (94%), M.P. 192-195 of N (2 diethylaminoethyl) 1-etl1y1-1,4-dihydro 6,7 methylenedioxy 4-oxo-3-quinoline carboxamide, M.P. 199-201.
A nalysis.Calcd. for C H N (percent): C, 63.49; H, 7.01; N, 11.69. Found (percent): C, 63.57; H, 7.05; N, 11.76.
Example 2 Following the procedure of Method C, Example 1, and using m-anisidine there was obtained 1-ethyl-1,4-dihydro- N (m methoxyphenyl) 6,7-methylenedioxy-4-oxo3- quinoline carboxamide, M.P. 240-241 Analysis.-Calcd. for C H N 0 (percent): C, 65.56; H, 4.95; N, 7.65. Found (percent): C, 65.50; H, 5.02; 'N, 7.41.
METHOD C 1-ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxyquinoline- 3-hydroxamic acid.Hydroxylamine hydrochloride (2.1 g., 0.03 mole) was added to a mixture of 4.2 g. (0.015 mole) of l-ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxyquinoline-3-carbonyl chloride in 25 m1. of pyridine. After stirring for 2 hr., the mixture was heated for 3 hr. on a steam bath. The pyridine was removed under aspirator vacuum and the residue was recrystallized from 90% aqueous ethanol to yield 4.0 g. of light yellow crystals (96%) of 1-ethyl-1,4-dihydro-6,7-methylenedioxy-4-oxo- S-quinoline hydroxamic acid, M.P. 265-268. The analytical sample from 95% ethanol had M.P. 269270.
Analysis.-Calcd. for C H N O (percent): C, 56.52; H, 4.38; N, 10.14. Found (percent): C, 56.77; H, 4.47; N, 10.10.
METHOD D Ethyl[ (1 ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxyquinoline 3 yl)carbonyl]carbamates.-A mixture of 8.4 g. (0.03 mole) of l-ethyl-1,4-dihydro-4-oxo-6,7-methylenedioxyquinoline-3-carbonyl chloride, 5.3 g. of (0.06 mole) of ethyl carbamate and 100 ml. of pyridine was refluxed for 8 hr. The solvent was removed in vacuo and the residue triturated with water and recrystallized from 0 0 3 C-R1 a I l wherein R is lower alkyl, hydroxy-lower alkyl, carboxylower alkyl, lower alkenyl, or cycloalkyl, in which cycloalkyl has from 3 to 8 carbon atoms; R is NHOH, NHCOOR NH-Q-ORz, and OCHzCHzN\ in which R is lower alkyl.
2. The compound of claim 1 wherein R is C H and R is NHOH.
3. The compound of claim 1 wherein R is C l-I and R1 iS 4. The compound of claim 1 wherein R is C H and R1 is OCHB 5. The compound of claim 1 wherein R is C H and R1 is OCH2CH2N(C2H5)2.
References Cited UNITED STATES PATENTS 2,614,121 10/1952 Price et al 260--287 X 3,172,811 3/1965 Kaminsky et al. 260287 X 3,287,458 ll/1966 Kaminsky et al 260-287 3,290,315 12/ 1966 Watson 260-287 3,397,208 8/ 1968 Berman 260-287 DONALD G. DAUS, Primary Examiner US. Cl. X.R.
US639304A 1967-05-18 1967-05-18 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid Expired - Lifetime US3524858A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63930467A 1967-05-18 1967-05-18

Publications (1)

Publication Number Publication Date
US3524858A true US3524858A (en) 1970-08-18

Family

ID=24563571

Family Applications (1)

Application Number Title Priority Date Filing Date
US639304A Expired - Lifetime US3524858A (en) 1967-05-18 1967-05-18 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid

Country Status (6)

Country Link
US (1) US3524858A (en)
CA (1) CA918665A (en)
DE (1) DE1770447A1 (en)
FR (1) FR8415M (en)
GB (1) GB1220623A (en)
SE (1) SE342450B (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3896131A (en) * 1971-12-30 1975-07-22 Riker Laboratories Inc Substituted benzo(ij)quinolizine-2-carboxylic acids and derivatives thereof
US3905982A (en) * 1973-07-23 1975-09-16 Searle & Co 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds
US3907808A (en) * 1971-05-17 1975-09-23 Sterling Drug Inc 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives
USB571638I5 (en) * 1973-07-23 1976-03-09
US3966743A (en) * 1968-07-23 1976-06-29 Boehringer Mannheim G.M.B.H. Ortho fused cycloalkano-4-quinolone-3-carboxylic acid derivatives
US3985882A (en) * 1972-11-02 1976-10-12 Riker Laboratories, Inc. Substituted benzo[ij]quinolinzine-2-carboxylic acids and derivatives thereof as bactericidal agents
US3992540A (en) * 1974-08-13 1976-11-16 Roussel-Uclaf 3-Quinoline-substituted 4-oxy-carboxamides
US4014877A (en) * 1972-11-02 1977-03-29 Riker Laboratories, Inc. Substituted benzo[ij]quinolizine-2-carboxylic acids and derivatives thereof
US4117136A (en) * 1976-08-19 1978-09-26 Sumitomo Chemical Company, Ltd. Systemic antimicrobial quinolines for plant disease
US4192876A (en) * 1975-07-23 1980-03-11 Sandoz, Inc. 4-Hydroxy-3-nitro-quinoline-2(1H)-ones
US4216324A (en) * 1978-12-26 1980-08-05 E. I. Du Pont De Nemours And Company 1-Difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
US4273930A (en) * 1977-06-20 1981-06-16 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acid esters
US4281131A (en) * 1977-06-20 1981-07-28 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acids and salts thereof
US4284777A (en) * 1978-12-26 1981-08-18 E. I. Du Pont De Nemours And Company Antibacterials: 1-difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its esters
FR2564832A1 (en) * 1984-05-23 1985-11-29 Panmedica Sa NOVEL N-ACYL DERIVED FROM AMINO ACIDS AND THEIR ESTERS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING SAME
WO1997004779A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
WO1997004775A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
WO2006002421A3 (en) * 2004-06-24 2006-09-21 Vertex Pharma Modulators of atp-binding cassette transporters
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
US20100184739A1 (en) * 2004-06-24 2010-07-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
US20110064811A1 (en) * 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2502912A2 (en) * 2004-06-24 2012-09-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RU2525115C2 (en) * 2004-06-24 2014-08-10 Вертекс Фармасьютикалз Инкорпорейтед Method of modulating transporters of atp-binding cassette
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1194219B (en) * 1962-01-12 1965-06-03 Schaefer & Kind Armaturenfabri Quick-acting shut-off valve with a non-rising twist grip
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2614121A (en) * 1946-03-01 1952-10-14 Charles C Price Process for making intermediates for producing basic compounds
US3172811A (en) * 1965-03-09 Quinolone proteus infection treatment
US3287458A (en) * 1963-12-12 1966-11-22 Warner Lambert Pharmaceutical 1, 4-dihydro-1-lower alkyl-6, 7-methylene-dioxy-4-oxo-3-quinoline-carboxylic acid
US3290315A (en) * 1962-04-09 1966-12-06 Norwich Pharma Co Esters of 6, 7-di (lower) alkoxy-4-hydroxy-3-quinolinecarboxylic acid
US3397208A (en) * 1965-02-24 1968-08-13 Norwich Pharma Co Method for preparing 4-hydroxy-6, 7-dialkoxy-3-carboalkoxyquinolines and novel 4-chloro-6, 7-dialkoxy-3-carboalkoxyquinolines useful therein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172811A (en) * 1965-03-09 Quinolone proteus infection treatment
US2614121A (en) * 1946-03-01 1952-10-14 Charles C Price Process for making intermediates for producing basic compounds
US3290315A (en) * 1962-04-09 1966-12-06 Norwich Pharma Co Esters of 6, 7-di (lower) alkoxy-4-hydroxy-3-quinolinecarboxylic acid
US3287458A (en) * 1963-12-12 1966-11-22 Warner Lambert Pharmaceutical 1, 4-dihydro-1-lower alkyl-6, 7-methylene-dioxy-4-oxo-3-quinoline-carboxylic acid
US3397208A (en) * 1965-02-24 1968-08-13 Norwich Pharma Co Method for preparing 4-hydroxy-6, 7-dialkoxy-3-carboalkoxyquinolines and novel 4-chloro-6, 7-dialkoxy-3-carboalkoxyquinolines useful therein

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966743A (en) * 1968-07-23 1976-06-29 Boehringer Mannheim G.M.B.H. Ortho fused cycloalkano-4-quinolone-3-carboxylic acid derivatives
US3907808A (en) * 1971-05-17 1975-09-23 Sterling Drug Inc 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3896131A (en) * 1971-12-30 1975-07-22 Riker Laboratories Inc Substituted benzo(ij)quinolizine-2-carboxylic acids and derivatives thereof
US3985882A (en) * 1972-11-02 1976-10-12 Riker Laboratories, Inc. Substituted benzo[ij]quinolinzine-2-carboxylic acids and derivatives thereof as bactericidal agents
US4014877A (en) * 1972-11-02 1977-03-29 Riker Laboratories, Inc. Substituted benzo[ij]quinolizine-2-carboxylic acids and derivatives thereof
US3905982A (en) * 1973-07-23 1975-09-16 Searle & Co 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds
USB571638I5 (en) * 1973-07-23 1976-03-09
US4001244A (en) * 1973-07-23 1977-01-04 G. D. Searle & Co. 1-aryl-3,4-dihydro-2(1h)-isoquinoline carbonyl chlorides
US3992540A (en) * 1974-08-13 1976-11-16 Roussel-Uclaf 3-Quinoline-substituted 4-oxy-carboxamides
US4192876A (en) * 1975-07-23 1980-03-11 Sandoz, Inc. 4-Hydroxy-3-nitro-quinoline-2(1H)-ones
US4117136A (en) * 1976-08-19 1978-09-26 Sumitomo Chemical Company, Ltd. Systemic antimicrobial quinolines for plant disease
US4273930A (en) * 1977-06-20 1981-06-16 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acid esters
US4281131A (en) * 1977-06-20 1981-07-28 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acids and salts thereof
US4216324A (en) * 1978-12-26 1980-08-05 E. I. Du Pont De Nemours And Company 1-Difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
US4284777A (en) * 1978-12-26 1981-08-18 E. I. Du Pont De Nemours And Company Antibacterials: 1-difluoromethyl-6,7-methylenedioxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and its esters
FR2564832A1 (en) * 1984-05-23 1985-11-29 Panmedica Sa NOVEL N-ACYL DERIVED FROM AMINO ACIDS AND THEIR ESTERS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING SAME
EP0165155A1 (en) * 1984-05-23 1985-12-18 S.A. PANMEDICA Société dite: N-acyl aminoacid derivatives and their esters, process for their preparation and medicaments containing them
WO1997004779A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
WO1997004775A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
AU695132B2 (en) * 1995-08-02 1998-08-06 Darwin Discovery Limited Quinolones and their therapeutic use
US5891878A (en) * 1995-08-02 1999-04-06 Chiroscience Limited Quinolones and their therapeutic use
EP2502912A2 (en) * 2004-06-24 2012-09-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8741925B2 (en) 2004-06-24 2014-06-03 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20080071095A1 (en) * 2004-06-24 2008-03-20 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP3705477A1 (en) * 2004-06-24 2020-09-09 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20090227797A1 (en) * 2004-06-24 2009-09-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20090298876A1 (en) * 2004-06-24 2009-12-03 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20100184739A1 (en) * 2004-06-24 2010-07-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
CN101006076B (en) * 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Modulators of ATP-binding cassette transporters
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8101767B2 (en) 2004-06-24 2012-01-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2012056963A (en) * 2004-06-24 2012-03-22 Vertex Pharmaceuticals Inc Modulator of atp-binding cassette transporter
JP2012062319A (en) * 2004-06-24 2012-03-29 Vertex Pharmaceuticals Inc Modulator of atp-binding cassette transporter
JP2012107069A (en) * 2004-06-24 2012-06-07 Vertex Pharmaceuticals Inc Modulator of atp-binding cassette transporter
WO2006002421A3 (en) * 2004-06-24 2006-09-21 Vertex Pharma Modulators of atp-binding cassette transporters
US8324242B2 (en) 2004-06-24 2012-12-04 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
AU2010249302B2 (en) * 2004-06-24 2013-01-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
CN104788328B (en) * 2004-06-24 2017-09-12 沃泰克斯药物股份有限公司 The adjusting control agent of ATP combination cassette transporters
CN101935301B (en) * 2004-06-24 2013-10-16 沃泰克斯药物股份有限公司 Modulators of ATP-binding cassette transporters
EP2502912A3 (en) * 2004-06-24 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2502911A3 (en) * 2004-06-24 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2502914A3 (en) * 2004-06-24 2013-12-04 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8614327B2 (en) 2004-06-24 2013-12-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8629162B2 (en) 2004-06-24 2014-01-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2008504291A (en) * 2004-06-24 2008-02-14 バーテックス　ファーマシューティカルズ　インコーポレイテッド ATP-binding cassette transporter modulator
CN103641765B (en) * 2004-06-24 2016-08-17 沃泰克斯药物股份有限公司 ATP-combines the adjusting control agent of cassette transporters
RU2525115C2 (en) * 2004-06-24 2014-08-10 Вертекс Фармасьютикалз Инкорпорейтед Method of modulating transporters of atp-binding cassette
US9090619B2 (en) 2004-06-24 2015-07-28 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2014156468A (en) * 2004-06-24 2014-08-28 Vertex Pharmaceuticals Inc Modulators of atp-binding cassette transporters
US8829204B2 (en) 2004-06-24 2014-09-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CN101891680B (en) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Modulators of ATP-binding cassette transporters
EP2530075A3 (en) * 2004-06-24 2014-12-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
US8410274B2 (en) 2005-12-28 2013-04-02 Vertex Pharmaceuticals Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8754224B2 (en) 2005-12-28 2014-06-17 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20110064811A1 (en) * 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9139530B2 (en) 2005-12-28 2015-09-22 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
GB1220623A (en) 1971-01-27
SE342450B (en) 1972-02-07
FR8415M (en) 1971-06-10
CA918665A (en) 1973-01-09
DE1770447A1 (en) 1972-03-16

Similar Documents

Publication Publication Date Title
US3524858A (en) 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
EP0682027B1 (en) Pyrrolopyrimidine derivatives with antiproliferative action
EP0091241B1 (en) Condensed pyrrolinone derivatives, and their production
DE69434380T2 (en) Pyridazino-quinoline compounds
US3287458A (en) 1, 4-dihydro-1-lower alkyl-6, 7-methylene-dioxy-4-oxo-3-quinoline-carboxylic acid
DE19838705A1 (en) New dihydro- (1,2,3) -triazolo- [4,5-d] pyrimidin-7-ones
DD272649A5 (en) NEW TRICYCLIC BENZIMIDAZOLE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT
US3506667A (en) Furo quinoline carboxylates
DE69823493T2 (en) TETRAHYDROPYRIDOVERBINDUNGEN
EP0422485A2 (en) Quinolone carboxylic acid derivatives, process for their preparation and their use
DD139854A5 (en) METHOD FOR PRODUCING NEW CONDENSED PYRIMIDINE DERIVATIVES
US3925391A (en) 2-Aminoalkyl tetrahydroquinolines
US3853872A (en) 2,3,4,5-substituted thiazoles
US3591697A (en) 1,4-dihydro - 1 - substituted-6,7-methylenedioxy-4-oxo -3-quinoline carboxylic acid antibacterial agents
US3573323A (en) 1,2,3,4,5,10-hexahydroazepino(2,3-b)indoles
EP0253171A1 (en) Pyrido[1,8]naphthyridinones, process for their preparation and their use and compositions containing them
CH644384A5 (en) IMIDAZO (2 ', 1': 2.3) THIAZOLO (5.4-C) PYRIDINE.
DE2832358C2 (en)
DE2233682A1 (en) 2- SQUARE CLAMP ON 3- (SUBST. AMINOMETHYL) -4-H-1,2,4-TRIAZOL-4-YL SQUARE CLIP ON -BENZOPHENONE, A PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINED
US3586675A (en) Fused thiazines
CH641800A5 (en) PYRIDO-PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THE MEDICINAL PRODUCT CONTAINING THESE COMPOUNDS.
US3673177A (en) Substituted 4-(anilinomethylene)-3-galanthamaninones
DE2615067A1 (en) NEW HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND COMPOSITIONS THEREOF
JP2541999B2 (en) Substituted quinoxalines and pharmaceutical compositions containing them
US3899490A (en) Hexahydro pyrazinoquinolines